Latest "ERSPC European Randomized Study Screening Prostate Cancer" News Stories

23:18 EST 15th December 2018 | BioPortfolio

Here are the most relevant search results for "ERSPC European Randomized Study Screening Prostate Cancer" found in our extensive news archives from over 250 global news sources.

More Information about ERSPC European Randomized Study Screening Prostate Cancer on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about ERSPC European Randomized Study Screening Prostate Cancer for you to read. Along with our medical data and news we also list ERSPC European Randomized Study Screening Prostate Cancer Clinical Trials, which are updated daily. BioPortfolio also has a large database of ERSPC European Randomized Study Screening Prostate Cancer Companies for you to search.

Showing "ERSPC European Randomized Study Screening Prostate Cancer" News Articles 1–25 of 39,000+

Extremely Relevant

Serum cholesterol and prostate cancer risk in the Finnish randomized study of screening for prostate cancer

What should doctors say to men asking for a PSA test?

A BMJ Rapid Recommendation in this issue1 reviews the evidence2 behind prostate cancer screening, including the latest large trial of prostate cancer screening with the prostate-specific antigen...

Prostate cancer screening with prostate-specific antigen (PSA) test: a clinical practice guideline

What you need to knowPSA testing has increased the number of men diagnosed with and treated for prostate cancer, but many of these men would never have experienced any symptoms or death from prostate...

African American Men and Prostate Cancer: Be Your Own Advocate and Understand Screening

This article addresses prostate cancer screening and the research around its potential benefits and harms.

Prostate Cancer Screening: Harms Beat Benefits

Dr Charles Vega comments on two studies, each looking at a different issue related to prostate cancer screening. Medscape Internal Medicine

Does Prostate Cancer Screening Decrease Mortality?

Dr Gerald Chodak discusses recent findings from a retrospective analysis on the magnitude of benefit with prostate cancer screening. Medscape Urology

More doctors say men should think twice about prostate cancer screening

(Reuters Health) - Most men shouldn't get routine prostate cancer screening because the potential benefits are small and there are clear harms, an international panel of experts concludes.

Have Relaxed PSA Recs Resulted in Unchecked Prostate Cancer?

Are patients being diagnosed with more advanced prostate cancer now that PSA screening recommendations have changed? Dr Chodak reviews a study seeking to answer this question. Medscape Urology

Highlights of USPSTF Updates to Prostate Cancer Screening Guidelines

Alex H. Krist, MD, MPHDavid F. Penson, MD, MPH

Medical News Today: Is regular screening for prostate cancer really necessary?

A panel of experts from the United Kingdom is asking whether regular screening for prostate cancer actually brings enough benefits to outweigh the risks.

Surgery May Benefit Some With Early Prostate Cancer: Study

WEDNESDAY, Dec. 12, 2018 -- For certain men with early prostate cancer, choosing surgery over "watchful waiting" may add a few years to their lives, a new study suggests. European researchers found that among nearly 700 men with earlier-stage...

USPSTF Recs on Prostate Cancer Screening: New or Déjà Vu?

The USPSTF's recently updated prostate cancer screening guidelines will challenge physicians to deliver accurate information to patients quickly and easily, argues Dr Gerald Chodak. Medscape Urology

GU/Prostate Cancer | Medscape

Review in-depth clinical information, latest medical news, and guidelines on prostate cancer and prostate cancer treatment including prostate cancer surgery. Learn about prostate cancer prognosis for advanced prostate cancer.

PSA Testing Not Recommended for Prostate Cancer Screening

THURSDAY, Sept. 6, 2018 -- Prostate cancer screening with prostate-specific antigen (PSA) testing is not recommended, although certain groups of men are more likely to undergo testing, according to a review and recommendations published online Sept....

Prostate Cancer Screening: No Effect on Overall Mortality

Screening for prostate cancer may result in a small absolute benefit in disease-specific mortality over 10 years but does not improve overall mortality. Medscape Medical News

Midlife PSA Predicts Aggressive Prostate Cancer in Black Men

THURSDAY, Oct. 11, 2018 -- Midlife levels of prostate-specific antigen (PSA) strongly predict future development of aggressive prostate cancer among black men, according to a study published online Sept. 17 in European Urology. Mark A. Preston,...

Men with aggressive prostate cancer may get new powerful drug option

(Northwestern University) A double-blind, randomized phase III trial shows a drug currently used to treat men with metastatic, advanced prostate cancer significantly lowered the risk of metastasis or death when used in men with non-metastatic castrate-resistant prostate cancer and a rising PSA level.

Nymox Reports 78 Month Results From Biopsy and Surgery Confirmed Prospective Randomized NX03-0040 Prostate Cancer Study of Fexapotide Triflutate: Gleason Grade Progression Reduced by 81% Overall and Fexapotide 15mg Minimal Treatment Leads to 73% Long-Term

HASBROUCK HEIGHTS, N.J., Oct. 09, 2018 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) is pleased to announce today important new long-term clinical trial results from the Company's 146 patient Phase IIb NX03-0040 Fexapotide (FT) U.S. study for low grade localized prostate cancer. All patients in the 78 month study had greater than or equal to 56 months from the time of enro...

Large U.S. Study Targets Prostate Cancer in Black Men

MONDAY, July 23, 2018 -- Black men in the United States have higher rates of aggressive prostate cancer than other males. Now, a $26.5 million study is underway to figure out why. The U.S. National Institutes of Health and the Prostate Cancer...

Early PSA testing could help predict prostate cancer among black men

(H. Lee Moffitt Cancer Center & Research Institute) In a new study published in European Urology, Moffitt Cancer Center researchers, along with colleagues at Harvard T.H. Chan School of Public Health and Brigham and Women's Hospital in Boston, demonstrated that a baseline prostate-specific antigen (PSA) level obtained from black men between ages 40 and 60 can strongly predict future development of...

How overdiagnosis and other harms can undermine the benefits of screening: A new primer in our toolkit

  September marks National Prostate Health Month, when hospitals and urology practices push free prostate cancer screening. It’s also when we at publish our annual analysis of why these promotions — and their “screening saves lives” message — are bad for men. To help readers understand the issue more clearly, we’ve published an expande...

Study identifies a genetic driver of deadly prostate cancer

(Cedars-Sinai Medical Center) A new study has identified a novel molecular driver of lethal prostate cancer, along with a molecule that could be used to attack it. The findings were made in laboratory mice. If confirmed in humans, they could lead to more effective ways to control certain aggressive types of prostate cancer, the second-leading cause of cancer death for men in the US.

Should I Get Screened for Prostate Cancer?

Source: Centers for Disease Control and PreventionRelated MedlinePlus Pages: Prostate Cancer Screening

Prostate cancer care for older men estimated to cost Medicare $1.2 billion

(UNC Lineberger Comprehensive Cancer Center) Researchers examined the costs associated with screening for prostate cancer, including treatment, for three years after diagnosis. They estimated that for men diagnosed in each of 2004, 2005, 2006, and 2007, the total cost for treating and screening for each group would be $1.2 billion for three years after diagnosis.

Prostate cancer care for older men estimated to cost Medicare $1.2 billion – Medical Xpress

Medical XpressProstate cancer care for older men estimated to cost Medicare $1.2 billionMedical XpressResearchers from the University of North Carolina Lineberger Comprehensive Cancer Center estimate that screening for and treating prostate cancer in men aged 70 years or older, which is not recommended by national guidelines, cost Medicare more than ...How Do You Spot Prostate Cancer Early On?Tech...

Quick Search


News Quicklinks